Literature DB >> 19608644

Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1.

Ushma R Jag1, Jiri Zavadil, Frederick M Stanley.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is an important regulator of fibrinolysis. PAI-1 levels are elevated in type 2 diabetes, and this elevation correlates with macro- and microvascular complications of diabetes. However, the mechanistic link between insulin and up-regulation of PAI-1 is unclear. Here we demonstrate that overexpression of Forkhead-related transcription factor (Fox)O1, FoxO3a, and FoxC1 augment insulin's ability to activate the PAI-1 promoter. In addition, insulin treatment promotes the phosphorylation of nuclear and cytoplasmic Fox03a and an increase of cytoplasmic Fox03a. In contrast, insulin treatment led to the accumulation of phospho-Fox01 only in the cytoplasm. Furthermore, insulin also increased the ability of chimeric LexA-FoxO1, LexA-FoxO3a, and LexA-FoxC1 proteins to increase the activity of a LexA reporter, suggesting that the effect of insulin on FoxO3a was direct. Using small interfering RNA to specifically deplete each of the Fox transcription factors tested, we demonstrate that only reduction of FoxO3a inhibits insulin-increased PAI-1-Luc expression and PAI-1 mRNA accumulation. Finally, chromatin immunoprecipitation assays confirm the presence of FoxO3a on the PAI-1 promoter. These results suggest that FoxO3a mediates insulin-increased PAI-1 gene expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608644      PMCID: PMC2754891          DOI: 10.1210/me.2008-0421

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  85 in total

1.  Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes.

Authors:  Christian Wolfrum; Esra Asilmaz; Edlira Luca; Jeffrey M Friedman; Markus Stoffel
Journal:  Nature       Date:  2004-12-23       Impact factor: 49.962

2.  Role of the FOXC2 -512C>T polymorphism in type 2 diabetes: possible association with the dysmetabolic syndrome.

Authors:  E Carlsson; L Groop; M Ridderstråle
Journal:  Int J Obes (Lond)       Date:  2005-03       Impact factor: 5.095

3.  Foxc2 is a common mediator of insulin and transforming growth factor beta signaling to regulate plasminogen activator inhibitor type I gene expression.

Authors:  Hideo Fujita; Myengmo Kang; Mesut Eren; Linda A Gleaves; Douglas E Vaughan; Tsutomu Kume
Journal:  Circ Res       Date:  2006-02-02       Impact factor: 17.367

4.  Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects.

Authors:  F Carmassi; M Morale; L Ferrini; G Dell'Omo; M Ferdeghini; R Pedrinelli; F De Negri
Journal:  Am J Med       Date:  1999-10       Impact factor: 4.965

5.  Fibrin fragment induction of plasminogen activator inhibitor transcription is mediated by activator protein-1 through a highly conserved element.

Authors:  M A Olman; J S Hagood; W L Simmons; G M Fuller; C Vinson; K E White
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

6.  The FOXC2 C-512T polymorphism is associated with obesity and dyslipidemia.

Authors:  Emma Carlsson; Peter Almgren; Johan Hoffstedt; Leif Groop; Martin Ridderstråle
Journal:  Obes Res       Date:  2004-11

7.  A novel frameshift mutation of FOXC2 gene in a family with hereditary lymphedema-distichiasis syndrome associated with renal disease and diabetes mellitus.

Authors:  Cagri Yildirim-Toruner; Kavitha Subramanian; Lamya El Manjra; Emily Chen; Stanley Goldstein; Emilia Vitale
Journal:  Am J Med Genet A       Date:  2004-12-15       Impact factor: 2.802

8.  Expression and intracellular localization of FKHRL1 in mammary gland neoplasms.

Authors:  Gui-Shan Jin; Eisaku Kondo; Takayoshi Miyake; Masao Shibata; Takako Takashima; Yi-Xuan Liu; Kazuhiko Hayashi; Tadaatsu Akagi; Tadashi Yoshino
Journal:  Acta Med Okayama       Date:  2004-08       Impact factor: 0.892

Review 9.  Role of IkappaB kinase in tumorigenesis.

Authors:  Mickey C-T Hu; M C Hung
Journal:  Future Oncol       Date:  2005-02       Impact factor: 3.404

10.  Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.

Authors:  Jennifer Altomonte; Lin Cong; Sonal Harbaran; Anja Richter; Jing Xu; Marcia Meseck; Hengjiang Henry Dong
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

View more
  11 in total

Review 1.  The Vasculature in Prediabetes.

Authors:  David H Wasserman; Thomas J Wang; Nancy J Brown
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

2.  Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity.

Authors:  Adam S Potter; Angelo J Casa; Adrian V Lee
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

3.  High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells.

Authors:  Luis Antonio Flores-López; María Guadalupe Martínez-Hernández; Rubí Viedma-Rodríguez; Margarita Díaz-Flores; Luis Arturo Baiza-Gutman
Journal:  Cell Oncol (Dordr)       Date:  2016-04-22       Impact factor: 6.730

4.  Clinical mesenchymal stromal cell products undergo functional changes in response to freezing.

Authors:  Kathryn Pollock; Darin Sumstad; Diane Kadidlo; David H McKenna; Allison Hubel
Journal:  Cytotherapy       Date:  2014-10-24       Impact factor: 5.414

5.  Effect of Insulin-Regulated FOXC2 Expression in Adipocyte Differentiation and Insulin Resistance.

Authors:  Xuxiang Zhang; Yuming Wang; Fan Zuo; Yandan Su; Hua Liu; Bin Wu; Xin Nian
Journal:  Diabetes Metab Syndr Obes       Date:  2020-08-06       Impact factor: 3.168

6.  The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.

Authors:  Michel Schmitt-Ney; Giovanni Camussi
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

7.  Statins Increase Plasminogen Activator Inhibitor Type 1 Gene Transcription through a Pregnane X Receptor Regulated Element.

Authors:  Frederick M Stanley; Kathryn M Linder; Timothy J Cardozo
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

8.  t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.

Authors:  Jessica L Christenson; Erin C Denny; Susan E Kane
Journal:  Oncotarget       Date:  2015-10-20

Review 9.  Autism spectrum disorders: let's talk about glucose?

Authors:  Silvia Hoirisch-Clapauch; Antonio E Nardi
Journal:  Transl Psychiatry       Date:  2019-01-31       Impact factor: 6.222

10.  Epigenetic clock analysis and increased plasminogen activator inhibitor-1 in high-functioning autism spectrum disorder.

Authors:  Satoshi Okazaki; Ryo Kimura; Ikuo Otsuka; Yasuko Funabiki; Toshiya Murai; Akitoyo Hishimoto
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.